Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points compared ...

An experimental drug has shown success in lowering the risk of genetically inherited heart disease by 94% during the second ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

The study demonstrates that this RNAi approach shuts down vital fungal genes, thereby inhibiting pathogen growth - a ...

Cucumber mosaic virus is a particularly devastating virus for crops. About 90 species of aphids transmit the virus, which ...

Unlocking the Potential of siRNA for Drug Development siRNA therapeutics represent a paradigm shift in targeted drug development by enabling precise gene silencing of disease-causing genes.

In this study, the authors demonstrated that exosomes can serve as delivery vehicles to introduce AGO2-loaded siRNA into the cytoplasm of bacteria, and in turn down-regulated gene expression of ...

Generation Bio Co. is developing siRNA therapeutics for T cell-driven autoimmune diseases using its T cell-selective lipid nanoparticle technology. This innovative delivery system aims to ...

RN0361 is a potential best-in-class APOC3 target siRNA utilizes Rona's proprietary siRNA conjugate and oligo chemistry platform GAIA to enable robust and durable hepatocyte-specific silencing via ...

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the evolving landscape of ...

Clinical Trial Growth & Future Outlook: Analysis of the 150+ industry-sponsored siRNA clinical trials conducted between 2020 and 2024, with a 79.5% CAGR reflecting significant industry investment.